TPWA
AUPH icon

Twin Peaks Wealth Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$30 – 387
2026
Q1 		$30 Buy
+2
New +$29 ﹤0.01% 2329
2025
Q3 		– Sell
-2
Closed -$23 – 322
2025
Q2 		$23 Buy
+2
New +$16 ﹤0.01% 2242

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's AUPH Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 2 shares — an estimated $30 sold.

Twin Peaks Wealth Advisors first reported a position in AUPH in Q2 2025 and held it in 2 quarters. The position peaked at $30 in Q1 2026. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 2 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $30.
  • Twin Peaks Wealth Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Aurinia Pharmaceuticals position peaked at $30 in Q1 2026.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.